b/hpiv3/hmpv-pref-a
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2024 (NCT06546423)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MetapneumovirusImmunity, active
Metapneumovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06546423 | Phase 1 | Jul 12, 2024 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester, Vanderbilt University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1